| Identification | Back Directory | [Name]
BIBN 4096BS | [CAS]
204697-65-4 | [Synonyms]
BIBN-4096
Olcegepant
BIBN 4096BS
BIBN 4096BS API Olcegepant
1-[3,5-Dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)-piperazine
Piperazine, 1-[3,5-dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)-
N-[2-[5-Amino-1(S)-[4-(4-pyridinyl)piperazin-1-ylcarbonyl]pentylamino]-1(R)-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl]-4-(2-oxo-1,2,3,4-tetrahydroquinazolin-3-yl)piperidine-1-carboxamide | [Molecular Formula]
C38H47Br2N9O5 | [MDL Number]
MFCD07772306 | [MOL File]
204697-65-4.mol | [Molecular Weight]
869.65 |
| Chemical Properties | Back Directory | [Boiling point ]
1091.9±65.0 °C(Predicted) | [density ]
1.497 | [storage temp. ]
Store at -20°C | [solubility ]
≥87 mg/mL in DMSO with gentle warming; insoluble in EtOH; insoluble in H2O | [form ]
Powder | [pka]
6.80±0.25(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Olcegepant is a potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist. Olcegepant displays high affinity for human CGRP receptors and exhibits no significant affinity for 75
other receptors. Olcegepant may a be viable option for the treatment of acute migraines. | [Biological Activity]
BIBN4096BS (Olcegepant) is a potent calcitonin gene-related peptide (CGRP) receptor antagonist with higher affinity/potency toward human over r at & mouse receptor (human/r at Ki = 14.4 pM/3.4 nM by binding assay; human/mouse Kb = 8 pM//7.711 nM by cellular cAMP assay). BIBN4096BS inhibits facial blood flow by electrical stimulation of marmoset monkey trigeminal ganglion (IC50 = 3 μg/kg i.v.) without any intrinsic cardiovascular effects. Studies using anaesthetized rats reveals th at BIBN4096BS antagonism against trigeminal nociceptive stimulation by capsaicin is limited to the spinal trigeminal nucleusbut not trigeminal ganglion. Also widely employed for in vivo studies in mice. | [in vivo]
Olcegepant (BIBN4096BS) in doses between 1 and 30 μg/kg (i.v.) inhibits the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys[2]. Pre-treatment with Olcegepant (900 μg/kg) inhibits the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%. In contrast, the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion is not changed by Olcegepant pre-treatment[4]. Olcegepant (0.3 to 0.9 mg/kg, i.v.) markedly reduces mechanical allodynia in CCI-ION rats. Olcegepant (0.6 mg/kg, i.v.) significantly reduces the number of c-Fos immunolabeled cells in spinal nucleus of the trigeminal nerve and upregulation of ATF3 transcript (a marker of neuron injury) but not that of interleukin-6 in trigeminal ganglion of CCI-ION rats[5]. | [target]
CGRP1 | [storage]
Store at -20°C |
|
|